Galapagos formed as a 50:50 joint venture between Crucell and Tibotec focuses on genomics-based internal discovery program with service activities. The company formed BioFocus DPI by acquiring BioFocus and drug discovery operations of Discovery Partners International. The company possesses two operating divisions - drug discovery and BioFocus DPI. Galapagos’ drug discovery division develops disease-modifying drugs in selected bone and joint disease areas while Galapagos’ BioFocus DPI service division offers target-to-candidate drug discovery products and services to pharmaceutical and biotech companies as well as to not-for-profit organizations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The target discovery platform of Galapagos is based in adenoviruses efficiently introduce human gene sequences into a wide variety of human primary cells to knock-in or knock-down specific proteins.